Skip to main content

Advertisement

Log in

Long-term protective effect of post-exposure Havrix TM administration during viral hepatitis Type A outbreaks

  • Infectious Diseases
  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

Abstract

Administration of human normal immunoglobulin (HNIG) post-exposure has been routinely used in Slovakia for outbreak control of hepatitis A, but requires deep intramuscular injection, provides only short-lived protection and is a human blood product. The protective effect of post-exposure administration of an inactivated hepatitis A vaccine was evaluated during 10 outbreaks in Slovakia. Direct contacts of confirmed hepatitis A cases received either: a single dose of hepatitis A vaccine (n = 2171) or immunoglobulin (HNIG, n = 3837). In the HNIG group the number of hepatitis A confirmed cases dropped within the first 7 weeks, however the decrease was not as rapid or as marked as that observed in the vaccinated group where the number of hepatitis A cases dropped within the first 4 weeks after vaccination. Among contacts, 67 cases of hepatitis A were detected during the maximum incubation period of 45 days: 16 cases (0.7%) in the vaccine group and 51 cases (1.3%) in the HNIG group (p  <  0.05). After two and three years respectively, 50 and 39 volunteers who had previously received one dose of hepatitis A vaccine received a booster dose and anti-HAV antibodies were measured. Differences in anti-HAV antibody GMCs before and after the booster were statistically significant. The longer time interval (3 years instead of 2) between primary vaccination and booster administration did not seem to impact the magnitude of the booster response. The results of this study show that active post-exposure immunisation with only one dose of inactivated vaccine confers high and long-term protection and effectively controls viral hepatitis A outbreaks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ALT:

alanine aminotransferase

AST:

aspartate aminotransferase

ELISA:

enzyme-linked immunosorbent assay

GMC:

geometric mean concentrations

HAV:

hepatitis A virus

HNIG:

human normal immunoglobulin

Ig:

immunoglobulin

IgG:

immunoglobulin G

IgM:

immunoglobulin M

mIU/ml:

milli-international units per milliliter

ml/kg:

milliliter per kilogram

p :

p-value

t :

Student’s statistic

References

  1. Advisory Committee on Immunization Practices (ACIP); Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006 May 19; 55(RR-7): 1–23

  2. Wheeler C, Vogt TM, Armstrong GL, et al. (2005) An outbreak of hepatitis A associated with green onions. N Engl J Med 353(9): 890–897

    Article  PubMed  CAS  Google Scholar 

  3. Tregnaghi M, Ussher J, Ruttimann R, Jalil M, Tanaka J, Safary A. Effect of the use of vaccine during an epidemic of Hepatitis A in a town in Argentina. Bol Venez Infectol 1997; 7 (Suppl.1)

  4. Trmal J, Jílková E, Zenková E, Ondřej J (1996) Vaccination of children against viral hepatitis A (HAV). Čs Pediat 51(11): 669–673

    Google Scholar 

  5. Werzberger A, Mensch B, Kuter B, et al. (1992) A controlled trial of formalin-inactivated hepatitis A vacccine in healthy children. N Engl J Med 327: 453–457

    Article  PubMed  CAS  Google Scholar 

  6. Kohl I, Príkazský V, Oleár V, van Hoecke C, André FE, Safary A. (1996) Protective effect of post-exposure HavrixTM administration under conditions of viral hepatitis A occurrence FIMSA. Adelaide, Australia, p. 100

    Google Scholar 

  7. Specialized State Health Institute. Analysis of the epidemiological situation in Slovakia in 1993. Banská Bystrica, Slovak Republic 1994: 6–8

  8. Specialized State Health Institute. Analysis of the epidemiological situation in Slovakia in 1995. Banská Bystrica, Slovak Republic, 1996: 16–17

  9. State Health Institute. Analysis of the epidemiological situation in Slovakia in 2001. Banská Bystrica, Slovak Republic, 2002: 24

  10. State Health Institute. Analysis of the epidemiological situation in Slovakia in 2000. Banská Bystrica, Slovak Republic, 2001: 23–26

  11. Behrens RH, Doherty JF (1993) Severe hepatitis A despite passive immunization. Lancet 341: 972

    Article  PubMed  CAS  Google Scholar 

  12. Príkazský V, Oleár V, Černoch A, Safary A, André FE (1994) Interruption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol 44: 457–459

    Article  PubMed  Google Scholar 

  13. McMahon BJ, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L. (1996) A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 150: 733–739

    PubMed  CAS  Google Scholar 

  14. Irwin DJ, Millership S (1999) Control of a community hepatitis outbreak using hepatitis A vaccine. Commun Dis Public Health 2(3): 184–187

    PubMed  CAS  Google Scholar 

  15. Poovorawan Y, Tieamboonlers A, Chumdermpadetsuk S, Gluck R, Cryz SJ Jr (1994) Control of a hepatitis A outbreak by active immunization of high-risk susceptible subjects. J Infect Dis 169: 229–230

    Google Scholar 

  16. Taliani G, Gaeta GB (2003) Hepatitis A: Post-exposure prophylaxis. Vaccine 21(19–20): 2234–2237

    Article  PubMed  Google Scholar 

  17. Sagliocca L, Amoroso P, Stroffolini T, Adamo B, Tosti ME, Lettieri G, Esposito C, Buonocore S, Pierri P, Mele A (1999) Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: A randomised trial. Lancet 353(9159): 1136–9

    Article  PubMed  CAS  Google Scholar 

  18. Hauri AM, Fischer E, Fitzenberger J, Uphoff H, Koenig C (2006) Active immunisation during an outbreak of hepatitis A in a German day-care centre. Vaccine 24(29–30): 5684–5689

    Article  PubMed  CAS  Google Scholar 

  19. Winokur PL, Stapleton JT (1992) Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 14(2): 580–586

    PubMed  CAS  Google Scholar 

  20. Irwin DJ, Millership S (2001) Antibody responses to Hepatitis A vaccine in healthy adults. Commun Dis Public Health 4(2): 139–40

    PubMed  CAS  Google Scholar 

  21. Khuroo MS (2003) Viral hepatitis in international travellers: Risks and prevention. Int J Antimicrob Agents 21(2): 143–52

    Article  PubMed  CAS  Google Scholar 

  22. van Herck K, van Damme P (2005) Prevention of hepatitis A by Havrix: A review. Expert Rev Vaccines 4(4): 459–71

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Funding: This study was co-funded by GlaxoSmithKline Biologicals and the Slovak Ministry of Health.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to I. Kohl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kohl, I., Němeček, V., Summerová, M. et al. Long-term protective effect of post-exposure Havrix TM administration during viral hepatitis Type A outbreaks. Eur J Epidemiol 21, 893–899 (2006). https://doi.org/10.1007/s10654-006-9081-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10654-006-9081-2

Keywords

Navigation